|  Sign up!  


Return to Course Listing



CME: Multiple Myeloma Pharmacotherapy: Therapeutic Updates, Best Practices, and Emerging Treatment Options


Program Description / Statement of Need:

In this online CME self-learning program:

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. While MM only makes up about 1% of all cancers, it the most common of the blood cancers, and its incidence has risen from the lower end of 22,000 cases per year five years ago to an estimated 26,850 in 2015; mortality rates have stayed consistent at approximately 11,000 per year. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites.


Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM. Moreover, professional guidelines are updated with frequency, and communicating related information to healthcare professionals in a timely manner is a demonstrated need. The literature suggests that practicing healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice, and awareness of professional guidelines is no exception. Recently published guidelines therefore also inherently suggest a gap in medical practice and justify the need for educational programming.





Faculty introduction, disclosures

Introduction content: cursory refresher and review

  • Epidemiology: statistics by severity
  • Causes and risk factors
  • Clinical features, presentation, and histopathology
  • Pathogenesis and the role of the immune system
  • Pretreatment evaluation
  • Risk stratification and disease staging
  • Transplant eligibility
  • Updates in biomarkers, staging, as applicable

Updates in treatment in patients with MM

  • Clinical trials: what is new, and how should it impact practice?
  • First-line pharmacotherapy and updates
  • Evaluation of treatment response
  • Treatment progression and treatment options
  • Options and goals in high-risk disease
  • Relapsed myeloma
  • Emerging therapeutic options for MM: what is on the horizon?
  • Clinical challenges including complication management
  • The role of the clinician as educator
  • Patient case(s)

Summary, conclusions, and best practice recap


Target Audience:

Health professionals specializing in: hematology, oncology, and healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with MM.

Program Objectives:

By the end of the session the participant will be able to:

    • Summarize recent updates in what is known about MM’s pathophysiology and diagnosis and how they relate to mechanisms of resistance to conventional therapy and targets for emerging therapy.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Describe the risks and benefits of profile of treatments for MM
    • Summarize the emerging therapies for MM and anticipate their place in therapy
    • Select a treatment regimen for a patient who has been treated previously, taking relevant biomarkers and previous clinical response into account


    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.


    Credit Designation: ScientiaCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.




    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-16-014-H01-P.  ACPE Accreditation effective 8/29/16, expires 8/29/18. 

    This is a Knowledge (K)-type activity.

    Release Date: August 29, 2016
    Expiration Date: August 29, 2018

    Faculty: Dimitrios Tzachanis MD, PhD

    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


    Faculty Disclosure:  Dimitrios Tzachanis, M.D., Ph.D., Assistant Clinical Professor of Medicine, University of California San Diego, La Jolla, CA has no relevant financial disclosures to report. 


    Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.


    Commercial Support Disclosure: This program is supported by an educational grant from AMGEN

    Additional Courses That Are Related To This Course

    Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

    Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices

    Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society for Clinical Oncology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

    Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society of Hematology (ASH 2016): Take-Aways, Emerging Practice Changes, and Barriers to their Implementation


    Viewing Instructions



    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    Mac OS 10.2.8
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh


    *Required to view Printable PDF Version


    Privacy Policy



    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.

    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

    Download the Presentation (optional)


    View the online program


    Perform Post-Test

    Complete the Symposium Evaluation and Request CE Certificate

This program is supported by an educational grant from AMGEN


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.